Frequency Of Antithyroid Antibodies Research Articles

Frequency of antithyroid antibodies in patients with primary biliary cholangitis.

Primary biliary cholangitis (PBC) is an autoimmune disease of liver that may be associated with other conditions, including autoimmune thyroid diseases. We aimed to investigate the frequency of anti-thyroperoxidase antibodies (TPO-Ab), antithyroglobulin antibodies (TG-Ab), and anti-thyrotropin receptor antibodies (TSHR-Ab) in Tunisian patients with PBC. Sera of 80 patients with PBC were collected over a 9-year period. A total of 189 healthy blood donors (HBD) were included in the control group. Measurements of TPO-Ab and TG-Ab were performed using indirect enzyme-linked immunosorbent assay (ELISA). Competitive ELISA was used to assess TSHR-Ab. Antithyroid antibodies (ATA) were significantly more frequent in PBC patients than in the control group (13.7% vs 1.6%; P < 10-3). Out of 11 patients with ATA, 10 (90.9%) were female. Nine patients and 2 HBD had TPO-Ab (11.2% vs 1%; P < 10-3). TG-Ab were more frequent in patients than in healthy subjects but the difference was not statistically significant (6.2% vs 1.6%; P = .1). TPO-Ab and TG-Ab were present together in 3 patients (3.7%). TSHR-Ab were absent in patients and controls. This study shows that PBC is associated with a high frequency of ATA but not TG-Ab or TSHR-Ab.

Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors.

Immune checkpoint inhibitors (ICI), such as programmed death-1 inhibitors (anti-PD1), have become a cornerstone for the treatment of different advanced cancers. These antibodies act as modulators of immune checkpoint proteins. However, ICI can lead to the breaking of immune self-tolerance, inducing autoimmune side effects (irAEs), including endocrinopathies. One of the most frequent endocrine irAE of anti-PD1 is thyroid dysfunction, but the exact mechanism of this disease still remains unknown. We conducted a descriptive retrospective study, analyzing 11 patients who received at least one dose of anti-PD1 (nivolumab or pembrolizumab) and presented thyroid irAEs. Data were collected between September 2015 and May 2018 in our hospital. The aim was to analyze the clinically relevant features of thyroid irAEs and the frequency of antithyroid antibodies (ATA) positivity observed on them. 8 of the 11 patients were treated with nivolumab and the other three patients received pembrolizumab. Six patients presented silent thyroiditis with a thyrotoxicosis phase; three patients developed directly primary/subclinical hypothyroidism and two patients showed primary hyperthyroidism. Thyroid autoantibodies (anti-Thyroglobulin and anti-Thyroid Peroxidase) were assessed in all the 11 patients, and only in two of them (18%) a positive titer was displayed. Anti-TSH receptor antibodies (TRAbs) were examined in five patients, three with painless thyroiditis at the time of thyrotoxicosis and two with primary hyperthyroidism, and they all had undetectable levels. In our sample of 11 Caucasian patients with thyroid dysfunction related with anti-PD1, we found low frequency of ATA positive titers, comparable to other recent reports in others ethnicities, which could suggest that silent thyroiditis due to pembrolizumab or nivolumab has a different pathogenesis from the classical autoimmune spontaneous thyroiditis. Further investigations are required to completely understand the immune mechanisms involved.

Thyroid-Related Autoantibodies in Tunisian Patients with Type 1 Diabetes

Aim. To evaluate, retrospectively, the frequency of antithyroid antibodies (ATA) in patients with type 1 diabetes (T1D). Materials and methods. Antithyroperoxidase antibodies (TPO-Ab), antithyroglobulin antibodies (TG-Ab), and antithyroid-stimulating hormone receptor antibodies (TSHR-Ab) were determined by enzyme-linked immunosorbent assay. Sera of 312 patients (166 children and 146 adults) with T1D were analyzed. Sera of 276 healthy subjects (87 children and 189 blood donors) served as controls. Results. Out of 312 patients with T1D, 44 (14%) had ATA (TPO-Ab or TG-Ab or TSHR-Ab). The frequency of ATA in patients with T1D was significantly higher than in the control group (14% vs. 2.8%; p < 10−5). ATA were significantly more frequent in adult patients with T1D than in the blood donor group (20% vs. 1.6%; p < 10−8). The frequency of ATA in adult patients was significantly higher than in pediatric patients (20% vs. 9%; p = 0.006). The frequency of TPO-Ab and TG-Ab was significantly higher in patients with T1D than in the control group (13.5% vs. 2%; p < 10−8 and 7% vs. 2.2%, p = 0.008), respectively. Out of 312 patients with T1D, only one had TSHR-Ab. The simultaneous presence of three autoantibodies was found in one patient with T1D. Conclusion. ATA were frequent in patients with T1D. Serological screening of autoimmune thyroid disease is suggested in patients with T1D.

Antibodies to thyroglobulin and thyroid peroxidase in rheumatoid arthritis: environmental and genetic associations

Recent years have seen the emergence and establishment of antibodies to citrullinated antigens as the primary diagnostic marker for rheumatoid arthritis (RA). Recent work has established the close link between...

Thyroid-related autoantibodies in Tunisian patients with coeliac disease

The aim of our study was to evaluate, retrospectively, the frequency of anti-thyroid antibodies (ATA) in coeliac disease (CD) patients. ELISA was used to determine the frequency of anti-thyroid stimulating hormone receptor antibodies, thyroperoxidase antibodies and thyroglobulin antibodies in sera of 104 adult patients with CD. Patients were divided into three groups: group I, 56 untreated patients; group II, 21 patients on a strict gluten-free diet (GFD); and group III, 27 patients who did not comply with a GFD. Sera of 189 healthy blood donors served as controls. Out of 104 patients with CD, five (4.8%) had ATA. The frequency of ATA found in the control group (1.6%) was not significantly different from that found in all CD patients. However, the frequency of ATA in CD patients on a GFD was significantly higher than that found in the control group (8.3% vs. 1.6%, p=0.03). The frequency of ATA in groups I, II and III was 1.8%, 9.5% and 7.4%, respectively. ATA were found in CD patients even on a GFD.

Quantificação de anticorpos antitireoperoxidase e antitireoglobulina, tireotrofina e tiroxina livre em gestantes normais

OBJETIVO: verificar a presença de anticorpos antitireoperoxidase (anti-TPO) e antitireoglobulina (anti-TG) e as concentrações plasmáticas de tireotrofina (TSH) e tiroxina livre (T4L) em gestantes normais. MÉTODOS: estudo transversal realizado no ambulatório de Pré-Natal da Santa Casa de Misericórdia de São Paulo (SP), no período de janeiro de 2003 a setembro de 2004. Foram incluídas 127 grávidas, residentes em São Paulo, com idades entre 14 e 44 anos e idade gestacional igual ou superior a 16 semanas, determinada por ultra-sonografia realizada antes da 20ª semana de gestação. Foram excluídas gestantes em uso de medicamentos ou história de tireoidopatia. Foram quantificados os anticorpos antitireoperoxidase e antitireoglobulina por imunoensaio quimioluminescente. A técnica de imunofluorimetria por tempo resolvido foi empregada para a determinação de tireotrofina e tiroxina livre. Para análise dos resultados, aplicou-se o teste t de Student, com significância de 5%. RESULTADOS: a freqüência dos anticorpos antitireoidianos foi 12,6% (8,6% de anticorpos anti-TPO, 4,6% de anticorpos anti-TG). A média das concentrações de TSH foi de 2,1±1,0 µU/mL e a média de T4L foi de 0,9±0,5 ng/dL. Observou-se alteração da função tireoidiana em dez gestantes (8%). Três delas tiveram diagnóstico de hipotireoidismo: uma na forma clínica da doença, com TSH aumentado e T4L diminuído; duas na forma subclínica, com TSH aumentado e T4L normal. Cinco mostraram valores de TSH diminuídos e de T4L aumentados, compatíveis com hipertireoidismo clínico, e duas tiveram diagnosticado hipertireoidismo subclínico, apenas com concentrações de TSH diminuídas. CONCLUSÕES: a freqüência de anticorpos antitireoidianos foi de 12,6% em gestantes, sendo os anticorpos antitireoperoxidase predominantes sobre os anticorpos antitireoglobulina. Verificaram-se disfunções da tireóide em 8% dos casos, com alterações de TSH e/ou T4L.

Thyroid autoimmunity in patients with recurrent spontaneous miscarriages

Recurrent spontaneous miscarriage (RSM) is a multifactorial problem. Auto- and alloimmune parameters have been implicated. Antithyroid antibodies (ATA) were tested in a group of women with RSM. The presence of antipatemal antibodies (APCA) was evaluated as an index of alloimmune contribution.Thirty euthyroid women with RSM (three or more consecutive miscarriages) aged 25–37 years were compared with 15 matched controls. Thyroid peroxidase (TPO) and thyroglobulin antibodies were tested with a chemiluminescence immunoassay and APCA were tested with a cross-match reaction. Results were compared using the chi-squared test.There was a higher frequency of ATA in women with RSM compared to controls (37% versus 13%, p < 0.05). Twenty of the women (67%) with RSM were tested negative for APCA, indicating an alloimmune contribution to their infertility. In this subgroup of women, the frequency of ATA continued to be higher than controls (40% versus 13%, p < 0.05).In conclusion, women with RSM, independent of APCA status, have a higher frequency of ATA. This may represent an additional marker for impaired regulation of the maternal immune system.

High frequencies of human T-lymphotropic virus type I (HTLV-I) infection and presence of HTLV-II proviral DNA in blood donors with anti-thyroid antibodies.

To investigate the relationship between human T-lymphotropic virus (HTLV) types I and II and the pathogenesis of autoimmune thyroid diseases, we examined serum anti-thyroid antibodies in 1019 blood donors with or without serum anti-HTLV-I antibody as well as proviral DNA for HTLV-II in leukocyte DNA by the polymerase chain reaction in 395 blood donors with or without anti-thyroid antibodies. The frequency of donors with anti-HTLV-I antibody who also showed anti-thyroid antibodies (7.9%) tended to be higher than that (6.3%) among donors who did not have the anti-HTLV-I antibody. The frequency of anti-thyroid antibodies in 125 young male donors aged 16-39 years with anti-HTLV-I antibody (4.8%) was significantly higher (P < 0.05) than that (0.6%) in 164 control donors without the antibody. In blood donors with anti-thyroid antibody, 25.0% of those with anti-HTLV-I antibody and 14.3% of those without the antibody had HTLV-II proviral DNA. In contrast, in donors without anti-thyroid antibody HTLV-II proviral DNA was detected in 2.3% of those with anti-HTLV-I antibody and in 0.6% of those without the antibody. Thus the detection rates in donors with anti-thyroid antibody were significantly higher (P < 0.001) than those in donors without the antibody, regardless of HTLV-I infection. These results suggest that HTLV-I infection and the presence of HTLV-II proviral DNA may be independently related to the pathogenesis of autoimmune thyroid diseases.

Alopecia Areata and Associated Diseases in Saudi Patients

Alopecia areata is a common presentation of Saudi patients seen at dermatology clinics. Although autoimmune factors have been suggested as pathogenic factors, alopecia areata remains a disease of unknown etiology. We investigated 92 patients with alopecia areata as compared to 88 sex- and age-matched healthy control subjects for the prevalence of associated diseases as well as abnormalities of thyroid function, and for the frequency of anti-thyroid antibodies. We found that atopy and pscychological stress constitute the most commonly associated disorders in our series. Except for two female patients with diabetes mellitus, none of the remaining patients displayed clinical evidence of endocrine or autoimmune disease. Only one patient had high T(3) and T(4) values and five (5.4%) had low titers of anti-thyroid antibodies, an acceptable finding for the normal population.